3M CO Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
3M CO (MMM) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of $937.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-21.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-07-21
- 3M CO income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was $937.00M, a 38.20% increase year-over-year.
- 3M CO income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was $657.00M, a 41.34% decline year-over-year.
- 3M CO income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was $573.00M, a 21.07% decline year-over-year.
- 3M CO income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was $839.00M, a 38.89% decline year-over-year.
- 3M CO income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2025 was $3.21B, a 20.05% decline from fiscal 2024.
- 3M CO income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2024 was $4.01B.
- 3M CO income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2023 was -$8.40B, a 309.26% decline from fiscal 2022.
- 3M CO income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2022 was $4.02B, a 32.15% decline from fiscal 2021.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $937.00M 10-Q · filed 2026-07-21 | $1.59B 10-Q · filed 2026-07-21 | $2.17B derived: sum of 3 quarters · filed 2026-07-21 | $3.01B derived: sum of 4 quarters · filed 2026-07-21 | ||||
| 2026-03-31 | $657.00M 10-Q · filed 2026-04-21 | $1.23B derived: sum of 2 quarters · filed 2026-04-21 | $2.07B derived: sum of 3 quarters · filed 2026-04-21 | $2.75B derived: sum of 4 quarters · filed 2026-07-21 | ||||
| 2025-12-31 | $573.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-03 | $1.41B derived: sum of 2 quarters · filed 2026-02-03 | $2.09B derived: sum of 3 quarters · filed 2026-07-21 | $3.21B 10-K · filed 2026-02-03 | ||||
| 2025-09-30 | $839.00M 10-Q · filed 2025-10-21 | $1.52B derived: sum of 2 quarters · filed 2026-07-21 | $2.64B 10-Q · filed 2025-10-21 | $3.36B derived: sum of 4 quarters · filed 2026-07-21 | ||||
| 2025-06-30 | $678.00M 10-Q · filed 2026-07-21 | $1.80B 10-Q · filed 2026-07-21 | $2.52B derived: sum of 3 quarters · filed 2026-07-21 | $3.90B derived: sum of 4 quarters · filed 2026-07-21 | ||||
| 2025-03-31 | $1.12B 10-Q · filed 2026-04-21 | $1.85B derived: sum of 2 quarters · filed 2026-04-21 | $3.22B derived: sum of 3 quarters · filed 2026-04-21 | $4.43B derived: sum of 4 quarters · filed 2026-04-21 | ||||
| 2024-12-31 | $726.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-03 | $2.10B derived: sum of 2 quarters · filed 2026-02-03 | $3.31B derived: sum of 3 quarters · filed 2026-02-03 | $4.01B 10-K · filed 2026-02-03 | ||||
| 2024-09-30 | $1.37B 10-Q · filed 2025-10-21 | $2.58B derived: sum of 2 quarters · filed 2025-10-21 | $3.29B 10-Q · filed 2025-10-21 | $3.91B derived: sum of 4 quarters · filed 2026-02-03 | ||||
| 2024-06-30 | $1.21B 10-Q · filed 2025-07-18 | $1.92B 10-Q · filed 2025-07-18 | $2.54B derived: sum of 3 quarters · filed 2026-02-03 | $16.00M derived: sum of 4 quarters · filed 2026-02-03 | ||||
| 2024-03-31 | $709.00M 10-Q · filed 2025-04-22 | $932.00M 10-Q · filed 2024-04-30 | $1.33B derived: sum of 2 quarters · filed 2026-02-03 | -$1.19B derived: sum of 3 quarters · filed 2026-02-03 | -$8.36B derived: sum of 4 quarters · filed 2026-02-03 | |||
| 2023-12-31 | $625.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-03 | -$1.90B derived: sum of 2 quarters · filed 2026-02-03 | -$9.07B derived: sum of 3 quarters · filed 2026-02-03 | -$8.40B 10-K · filed 2026-02-03 | -$7.00B 10-K · filed 2024-02-07 | |||
| 2023-09-30 | -$2.52B 10-Q · filed 2024-10-22 | -$2.07B 10-Q · filed 2023-10-24 | -$9.69B derived: sum of 2 quarters · filed 2024-10-22 | -$9.03B 10-Q · filed 2024-10-22 | -$7.93B 10-Q · filed 2023-10-24 | -$9.94B derived: sum of 4 quarters · filed 2025-02-05 | ||
| 2023-06-30 | -$7.17B 10-Q · filed 2024-07-26 | -$6.84B 10-Q · filed 2023-07-25 | -$6.50B 10-Q · filed 2024-07-26 | -$5.86B 10-Q · filed 2023-07-25 | -$7.42B derived: sum of 3 quarters · filed 2025-02-05 | -$3.56B derived: sum of 4 quarters · filed 2025-02-05 | ||
| 2023-03-31 | $979.00M 10-Q · filed 2024-04-30 | -$250.00M derived: sum of 2 quarters · filed 2025-02-05 | $3.61B derived: sum of 3 quarters · filed 2025-02-05 | $3.69B derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2022-12-31 | -$1.23B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-05 | $2.63B derived: sum of 2 quarters · filed 2025-02-05 | $2.71B derived: sum of 3 quarters · filed 2025-02-05 | $4.02B 10-K · filed 2025-02-05 | $5.78B 10-K · filed 2023-02-08 | |||
| 2022-09-30 | $3.86B 10-Q · filed 2023-10-24 | $3.94B derived: sum of 2 quarters · filed 2023-10-24 | $5.25B 10-Q · filed 2023-10-24 | $6.58B derived: sum of 4 quarters · filed 2024-02-07 | ||||
| 2022-06-30 | $83.00M 10-Q · filed 2023-07-25 | $1.38B 10-Q · filed 2023-07-25 | $2.72B derived: sum of 3 quarters · filed 2024-02-07 | $4.15B derived: sum of 4 quarters · filed 2024-02-07 | ||||
| 2022-03-31 | $1.30B 10-Q · filed 2023-04-25 | $2.64B derived: sum of 2 quarters · filed 2024-02-07 | $4.07B derived: sum of 3 quarters · filed 2024-02-07 | $5.59B derived: sum of 4 quarters · filed 2024-02-07 | ||||
| 2021-12-31 | $1.34B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-07 | $2.77B derived: sum of 2 quarters · filed 2024-02-07 | $4.29B derived: sum of 3 quarters · filed 2024-02-07 | $5.92B 10-K · filed 2024-02-07 | ||||
| 2021-09-30 | $1.43B 10-Q · filed 2022-10-25 | $2.96B derived: sum of 2 quarters · filed 2022-10-25 | $4.58B 10-Q · filed 2022-10-25 | $5.99B derived: sum of 4 quarters · filed 2023-02-08 | ||||
| 2021-06-30 | $1.52B 10-Q · filed 2022-07-27 | $3.15B 10-Q · filed 2022-07-27 | $4.56B derived: sum of 3 quarters · filed 2023-02-08 | $5.99B derived: sum of 4 quarters · filed 2023-02-08 | ||||
| 2021-03-31 | $1.63B 10-Q · filed 2022-04-26 | $3.04B derived: sum of 2 quarters · filed 2023-02-08 | $4.47B derived: sum of 3 quarters · filed 2023-02-08 | $5.77B derived: sum of 4 quarters · filed 2023-02-08 | ||||
| 2020-12-31 | $1.41B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-08 | $2.85B derived: sum of 2 quarters · filed 2023-02-08 | $4.15B derived: sum of 3 quarters · filed 2023-02-08 | $5.46B 10-K · filed 2023-02-08 | $5.39B 10-K · filed 2021-02-04 | |||
| 2020-09-30 | $1.44B 10-Q · filed 2021-10-26 | $1.42B 10-Q · filed 2020-10-27 | $2.74B derived: sum of 2 quarters · filed 2021-10-26 | $4.05B 10-Q · filed 2021-10-26 | $4.00B 10-Q · filed 2020-10-27 | $4.96B derived: sum of 4 quarters · filed 2022-04-26 | ||
| 2020-06-30 | $1.30B 10-Q · filed 2021-07-27 | $2.61B 10-Q · filed 2021-07-27 | $3.53B derived: sum of 3 quarters · filed 2022-04-26 | $5.12B derived: sum of 4 quarters · filed 2022-04-26 | ||||
| 2020-03-31 | $1.31B 10-Q · filed 2021-04-27 | $2.23B derived: sum of 2 quarters · filed 2022-04-26 | $3.81B derived: sum of 3 quarters · filed 2022-04-26 | |||||
| 2019-12-31 | $917.00M derived: 8-K 12 month − 10-Q 9 month · filed 2022-04-26 | $2.50B derived: sum of 2 quarters · filed 2022-04-26 | $4.53B 8-K · filed 2022-04-26 | $4.58B 10-K · filed 2021-02-04 | ||||
| 2019-09-30 | $1.59B 10-Q · filed 2020-10-27 | $3.61B 10-Q · filed 2020-10-27 | ||||||
| 2018-12-31 | $5.36B 10-K · filed 2021-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STRYKER CORP (SYK) | United States | $103.511B | 32.39 |
| BOSTON SCIENTIFIC CORP (BSX) | United States | $64.781B | 17.29 |
| BECTON DICKINSON & CO (BDX) | United States | $48.834B | 43.79 |
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| WEST PHARMACEUTICAL SERVICES INC (WST) | United States | $26.288B | 43.14 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |